Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.

Roussel R, Duran-García S, Zhang Y, Shah S, Darmiento C, Shankar RR, Golm GT, Lam RLH, O'Neill EA, Gantz I, Kaufman KD, Engel SS.

Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13574. [Epub ahead of print]

2.

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.

Lee SH, Gantz I, Round E, Latham M, O'Neill EA, Ceesay P, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

BMC Endocr Disord. 2017 Nov 6;17(1):70. doi: 10.1186/s12902-017-0219-x.

3.

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.

Home P, Shankar RR, Gantz I, Iredale C, O'Neill EA, Jain L, Pong A, Suryawanshi S, Engel SS, Kaufman KD, Lai E.

Diabetes Res Clin Pract. 2018 Apr;138:253-261. doi: 10.1016/j.diabres.2017.10.018. Epub 2017 Oct 24.

4.

Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.

Gantz I, Sokolova L, Jain L, Iredale C, O'Neill EA, Wei Z, Lam R, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

Clin Ther. 2017 Oct;39(10):2024-2037. doi: 10.1016/j.clinthera.2017.08.009. Epub 2017 Sep 18.

5.

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.

Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD, Lai E.

Cardiovasc Diabetol. 2017 Sep 11;16(1):112. doi: 10.1186/s12933-017-0593-8.

6.

Once-weekly oral antidiabetic agent and treatment satisfaction.

Gantz I.

Curr Med Res Opin. 2017 Nov;33(11):2095. doi: 10.1080/03007995.2017.1359520. Epub 2017 Aug 17. No abstract available.

PMID:
28737437
7.

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.

Gantz I, Okamoto T, Ito Y, Sato A, Okuyama K, O'Neill EA, Engel SS, Lai E; Omarigliptin Study 015 Group.

Diabetes Ther. 2017 Aug;8(4):793-810. doi: 10.1007/s13300-017-0270-7. Epub 2017 Jun 6.

8.

A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

Curr Med Res Opin. 2017 Oct;33(10):1861-1868. doi: 10.1080/03007995.2017.1335638. Epub 2017 Jun 28.

PMID:
28548024
9.

A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Shankar RR, Inzucchi SE, Scarabello V, Gantz I, Kaufman KD, Lai E, Ceesay P, Suryawanshi S, Engel SS.

Curr Med Res Opin. 2017 Oct;33(10):1853-1860. doi: 10.1080/03007995.2017.1335637. Epub 2017 Jun 23.

PMID:
28547998
10.

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.

Gantz I, Okamoto T, Ito Y, Okuyama K, O'Neill EA, Kaufman KD, Engel SS, Lai E; the Omarigliptin Study 020 Group.

Diabetes Obes Metab. 2017 Nov;19(11):1602-1609. doi: 10.1111/dom.12988. Epub 2017 Jul 6.

11.

A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.

Chacra A, Gantz I, Mendizabal G, Durlach L, O'Neill EA, Zimmer Z, Suryawanshi S, Engel SS, Lai E.

Int J Clin Pract. 2017 Jun;71(6). doi: 10.1111/ijcp.12955. Epub 2017 Apr 27.

PMID:
28449320
12.
13.

A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.

Moses RG, Round E, Shentu Y, Golm GT, O'neill EA, Gantz I, Engel SS, Kaufman KD, Goldstein BJ.

J Diabetes. 2016 Sep;8(5):701-11. doi: 10.1111/1753-0407.12351. Epub 2016 Feb 3.

PMID:
26625270
14.

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.

Sheu WH, Gantz I, Chen M, Suryawanshi S, Mirza A, Goldstein BJ, Kaufman KD, Engel SS.

Diabetes Care. 2015 Nov;38(11):2106-14. doi: 10.2337/dc15-0109. Epub 2015 Aug 26.

PMID:
26310692
15.

A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus.

Hauber AB, Tunceli K, Yang JC, Gantz I, Brodovicz KG, Alexander CM, Davies MJ, Radican L.

Diabetes Ther. 2015 Mar;6(1):75-84. doi: 10.1007/s13300-015-0094-2. Epub 2015 Jan 14.

16.

Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes.

Hauber AB, Han S, Yang JC, Gantz I, Tunceli K, Gonzalez JM, Brodovicz K, Alexander CM, Davies M, Iglay K, Zhang Q, Radican L.

Patient Prefer Adherence. 2013 Sep 18;7:937-49. doi: 10.2147/PPA.S43465. eCollection 2013.

17.

Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist.

Li XS, Nielsen J, Cirincione B, Li H, Addy C, Wagner J, Hartford A, Erondu N, Gantz I, Morgan J, Stone J.

AAPS J. 2010 Dec;12(4):537-47. doi: 10.1208/s12248-010-9212-2. Epub 2010 Jun 26.

18.

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes.

Kipnes MS, Hollander P, Fujioka K, Gantz I, Seck T, Erondu N, Shentu Y, Lu K, Suryawanshi S, Chou M, Johnson-Levonas AO, Heymsfield SB, Shapiro D, Kaufman KD, Amatruda JM.

Diabetes Obes Metab. 2010 Jun;12(6):517-31. doi: 10.1111/j.1463-1326.2009.01188.x.

PMID:
20518807
19.

A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet.

Wadden TA, Fujioka K, Toubro S, Gantz I, Erondu NE, Chen M, Suryawanshi S, Carofano W, Johnson-Levonas AO, Shapiro DR, Kaufman KD, Heymsfield SB, Amatruda JM.

Obesity (Silver Spring). 2010 Dec;18(12):2301-10. doi: 10.1038/oby.2010.67. Epub 2010 Apr 8.

20.

Randomized, controlled, double-blind trial of taranabant for smoking cessation.

Morrison MF, Ceesay P, Gantz I, Kaufman KD, Lines CR.

Psychopharmacology (Berl). 2010 Apr;209(3):245-53. doi: 10.1007/s00213-010-1790-2. Epub 2010 Feb 27.

PMID:
20191360
21.

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.

Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM.

Int J Obes (Lond). 2010 May;34(5):919-35. doi: 10.1038/ijo.2010.21. Epub 2010 Feb 16.

PMID:
20157323
22.

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.

Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN 3rd, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depré M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB.

Cell Metab. 2008 Jan;7(1):68-78. doi: 10.1016/j.cmet.2007.11.012.

23.

NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.

Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, Proietto J, Astrup A, Toubro S, Rissannen AM, Tonstad S, Haynes WG, Gottesdiener KM, Kaufman KD, Amatruda JM, Heymsfield SB.

Obesity (Silver Spring). 2007 Aug;15(8):2027-42.

24.

Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss.

Erondu N, Wadden T, Gantz I, Musser B, Nguyen AM, Bays H, Bray G, O'Neil PM, Basdevant A, Kaufman KD, Heymsfield SB, Amatruda JM.

Obesity (Silver Spring). 2007 Apr;15(4):895-905.

25.

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.

Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, Snyder K, Stevens C, Stroh MA, Zhu H, Wagner JA, Macneil DJ, Heymsfield SB, Amatruda JM.

J Clin Endocrinol Metab. 2007 May;92(5):1754-7. Epub 2007 Mar 6.

PMID:
17341568
26.

Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.

Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohórquez SM, Eng W, Långström B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB.

Cell Metab. 2006 Oct;4(4):275-82.

27.

Fat and energy partitioning: longitudinal observations in leptin-treated adults homozygous for a Lep mutation.

Heymsfield SB, Fong TM, Gantz I, Erondu N.

Obesity (Silver Spring). 2006 Feb;14(2):258-65.

28.

Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Pogozheva ID, Chai BX, Lomize AL, Fong TM, Weinberg DH, Nargund RP, Mulholland MW, Gantz I, Mosberg HI.

Biochemistry. 2005 Aug 30;44(34):11329-41.

29.

Chimeras of the agouti-related protein: insights into agonist and antagonist selectivity of melanocortin receptors.

Jackson PJ, Yu B, Hunrichs B, Thompson DA, Chai B, Gantz I, Millhauser GL.

Peptides. 2005 Oct;26(10):1978-87.

PMID:
16009463
30.
31.

Receptor-antagonist interactions in the complexes of agouti and agouti-related protein with human melanocortin 1 and 4 receptors.

Chai BX, Pogozheva ID, Lai YM, Li JY, Neubig RR, Mosberg HI, Gantz I.

Biochemistry. 2005 Mar 8;44(9):3418-31.

PMID:
15736952
32.

Structures of the agouti signaling protein.

McNulty JC, Jackson PJ, Thompson DA, Chai B, Gantz I, Barsh GS, Dawson PE, Millhauser GL.

J Mol Biol. 2005 Mar 4;346(4):1059-70. Epub 2005 Jan 25.

PMID:
15701517
33.

Inhibition of adipogenesis by ghrelin.

Zhang W, Zhao L, Lin TR, Chai B, Fan Y, Gantz I, Mulholland MW.

Mol Biol Cell. 2004 May;15(5):2484-91. Epub 2004 Mar 19.

34.

Inverse agonist activity of agouti and agouti-related protein.

Chai BX, Neubig RR, Millhauser GL, Thompson DA, Jackson PJ, Barsh GS, Dickinson CJ, Li JY, Lai YM, Gantz I.

Peptides. 2003 Apr;24(4):603-9.

PMID:
12860205
35.

Loops and links: structural insights into the remarkable function of the agouti-related protein.

Millhauser GL, McNulty JC, Jackson PJ, Thompson DA, Barsh GS, Gantz I.

Ann N Y Acad Sci. 2003 Jun;994:27-35. Review.

36.

Molecular determination of agouti-related protein binding to human melanocortin-4 receptor.

Yang Y, Chen M, Lai Y, Gantz I, Yagmurlu A, Georgeson KE, Harmon CM.

Mol Pharmacol. 2003 Jul;64(1):94-103.

PMID:
12815165
37.

Peptoid mimics of agouti related protein.

Thompson DA, Chai BX, Rood HL, Siani MA, Douglas NR, Gantz I, Millhauser GL.

Bioorg Med Chem Lett. 2003 Apr 17;13(8):1409-13.

PMID:
12668001
38.

The melanocortin system.

Gantz I, Fong TM.

Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E468-74. Review.

39.

Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity.

Jackson PJ, McNulty JC, Yang YK, Thompson DA, Chai B, Gantz I, Barsh GS, Millhauser GL.

Biochemistry. 2002 Jun 18;41(24):7565-72.

PMID:
12056887
40.

Molecular determinants of human melanocortin-4 receptor responsible for antagonist SHU9119 selective activity.

Yang Y, Chen M, Lai Y, Gantz I, Georgeson KE, Harmon CM.

J Biol Chem. 2002 Jun 7;277(23):20328-35. Epub 2002 Mar 23.

41.

Food deprivation-induced expression of minoxidil sulfotransferase in the hypothalamus uncovered by microarray analysis.

Li JY, Lescure PA, Misek DE, Lai YM, Chai BX, Kuick R, Thompson RC, Demo RM, Kurnit DM, Michailidis G, Hanash SM, Gantz I.

J Biol Chem. 2002 Mar 15;277(11):9069-76. Epub 2002 Jan 8.

42.

Functional properties of an agouti signaling protein variant and characteristics of its cognate radioligand.

Yang YK, Dickinson C, Lai YM, Li JY, Gantz I.

Am J Physiol Regul Integr Comp Physiol. 2001 Dec;281(6):R1877-86.

43.

Naturally occurring mutations in the melanocortin receptor 3 gene are not associated with type 2 diabetes mellitus in French Caucasians.

Hani EH, Dupont S, Durand E, Dina C, Gallina S, Gantz I, Froguel P.

J Clin Endocrinol Metab. 2001 Jun;86(6):2895-8.

PMID:
11397906
44.

Neuroendocrine regulation by the Agouti/Agrp-melanocortin system.

Barsh G, Gunn T, He L, Wilson B, Lu X, Gantz I, Watson S.

Endocr Res. 2000 Nov;26(4):571. No abstract available.

PMID:
11196430
45.

Agouti-related protein is a mediator of diabetic hyperphagia.

Qu SY, Yang YK, Li JY, Zeng Q, Gantz I.

Regul Pept. 2001 Apr 2;98(1-2):69-75.

PMID:
11179781
46.

Molecular determinants of ligand binding to the human melanocortin-4 receptor.

Yang YK, Fong TM, Dickinson CJ, Mao C, Li JY, Tota MR, Mosley R, Van Der Ploeg LH, Gantz I.

Biochemistry. 2000 Dec 5;39(48):14900-11.

PMID:
11101306
47.

Histamine H2 receptor mediated dual signaling: mapping of structural requirements using beta2 adrenergic chimeric receptors.

Wang LD, Gantz I, Butler K, Hoeltzel M, Del Valle J.

Biochem Biophys Res Commun. 2000 Sep 24;276(2):539-45.

PMID:
11027510
48.

Agouti-related protein-like immunoreactivity: characterization of release from hypothalamic tissue and presence in serum.

Li JY, Finniss S, Yang YK, Zeng Q, Qu SY, Barsh G, Dickinson C, Gantz I.

Endocrinology. 2000 Jun;141(6):1942-50.

PMID:
10830275
49.

Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain.

Bagnol D, Lu XY, Kaelin CB, Day HE, Ollmann M, Gantz I, Akil H, Barsh GS, Watson SJ.

J Neurosci. 1999 Sep 15;19(18):RC26.

50.

NMR structure of a minimized human agouti related protein prepared by total chemical synthesis.

Bolin KA, Anderson DJ, Trulson JA, Thompson DA, Wilken J, Kent SB, Gantz I, Millhauser GL.

FEBS Lett. 1999 May 21;451(2):125-31.

Supplemental Content

Support Center